Pacific Edge 2026 Annual Shareholders Meeting

20 August 2026
PACIFIC EDGE 2026 ANNUAL SHAREHOLDERS MEETING
DUNEDIN, New Zealand – Cancer diagnostics company Pacific Edge (NZX, ASX: PEB) is
holding its Annual Shareholder Meeting in Auckland this afternoon.
It attaches Chairman Simon Flood’s speech notes and the company’s presentation to
shareholders.
Released for and on behalf of Pacific Edge by Grant Gibson Chief Financial Officer.
Investors: Media:
Dr Peter Meintjes Richard Inder
Chief Executive The Project
Pacific Edge P: +64 21 645 643
P: +64 22 032 1263
OVERVIEW
Pacific Edge: www.pacificedgedx.com
Pacific Edge Limited (NZX/ ASX: PEB) is a global cancer diagnostics company leading the way
in the development and commercialization of bladder cancer diagnostic and prognostic tests
for patients presenting with hematuria or surveillance of recurrent disease. Headquartered in
Dunedin, New Zealand, the company provides its suite of Cxbladder tests globally through its
wholly owned, and CLIA certified, laboratories in New Zealand and the USA.
Cxbladder: www.cxbladder.com
Cxbladder is a suite of non-invasive genomic urine tests optimized for the risk stratification of
urothelial cancer in patients presenting with hematuria and those being monitored for recurrent
disease. The tests help improve the overall patient experience, while prioritizing time and
clinical resources to optimize practice workflow and improve efficiency.
Supported by over 20 years of research, Cxbladder’s evidence portfolio extends to more than
twenty-five peer reviewed publications, and Cxbladder Triage is now included in the American
Urological Association’s Microhematuria Guideline. To drive increased adoption and improved
patient health outcomes, Cxbladder is the focal point of numerous ongoing and planned studies
designed to generate further clinical utility evidence.
Cxbladder is available in the US, Australasia, and Israel and in markets throughout Asia and
South America. In the US, the test has been used by over 5,000 urologists who have ordered
more than 130,000 tests. In New Zealand, Cxbladder is accessible to around 70% of the
population via public healthcare and all residents have the option of buying the test online.

---

2026 ANNUAL SHAREHOLDERS’
MEETING PRESENTATION
Simon Flood
Chairman
Dr Peter Meintjes
Chief Executive Officer
20 August 2026
1

2
SIMON FLOOD
Chairman
CHAIRMAN’S ADDRESS

This presentation has been prepared by Pacific Edge Limited (PEL) to
provide PEL shareholders with information about PEL and its activities at
PEL’s 2026 Annual Shareholders’ Meeting (ASM).
A reference in this Important Notice and Disclaimer to the Information
means the information in this presentation, any written address released
to NZX and ASX in respect of this presentation, and any verbal remarks
made by PEL directors or management at the ASM (including answers to
shareholder questions) in respect of the matters addressed in this
presentation.
Unless otherwise specified, the Information is stated at the date of this
presentation.The Information should be read in conjunction with PEL’s
Annual Report, half-year financial statements, and continuous disclosure
announcements released to NZX and ASX at
•www.nzx.com/companies/PEB; and
•https://www.asx.com.au/markets/company/PEB
Information of a general nature
The Information is of a general nature only and does not purport to be
complete or comprehensive. It does not contain all the information that
a person may require in evaluating or making an investment decision in
respect of PEL shares. Nor does it take into account any person’s
objectives or circumstances.
Not an offer
The Information is for informational purposes only. It is not an invitation
or offer of securities for subscription, purchase or sale for any purpose
or in any jurisdiction.
Not financial product advice
The Information does not constitute legal, financial, tax, investment, or
financial product advice, and is not a recommendation to invest in or
deal with PEL shares.
Past performance, including past PEL share price performance, cannot be
relied on as an indicator of future performance, including in respect of
PEL’s future financial performance, PEL’s future financial position, or
future PEL share price performance. Any investment in PEL shares is
subject to various risks, including those set out on pages 26 to 28 of
PEL’s Capital Raising Presentation that was released by NZX and ASX on
11 May 2026. If you are considering investing in or dealing with PEL
shares, you are encouraged to read those risks carefully, and to seek
your own professional advice, before you do so.
Forward-looking statements
The Information contains forward-looking statements that relate to
future events, outcomes or circumstances. Forward-looking statements,
by their very nature, are based on assumptions, estimates or
expectations about the future and involve inherent risks and
uncertainties. Many of those assumptions, estimates, expectations, risks
and uncertainties are matters that are beyond PEL’s control. There is no
assurance that any forward-looking statement will be realized or
achieved. Actual results or circumstances could differ (potentially
materially) from those statements.
Non-GAAP financial information
The Information contains certain financial measures that are “non-GAAP
financial information” under the New Zealand Financial Markets
Authority Guidance Note on disclosing non-GAAP financial information
and “non-IFRS financial information” under the ASIC Regulatory Guide on
disclosing non-IFRS financial information (and potentially under other
regulatory guidelines or rules).
Such financial information and financial measures (including Cash Burn)
do not have standardized meanings prescribed under NZ IFRS or IFRS and
therefore, may not be comparable to similarly titled measures presented
by other entities, and should not be construed as an alternative to other
financial measures determined in accordance with NZ IFRS, or IFRS).
Currency
All dollar values to in the Information are in New Zealand dollars unless
otherwise stated.
Effect of rounding
A number of figures, amounts, percentages, estimates, calculations of
value and fractions in the Information are subject to the effect of
rounding. Accordingly, the actual calculations may differ.
Disclaimer
PEL has sought to use reasonable care to prepare the Information.
However, PEL and its related bodies corporate and affiliates, and their
respective directors, officers, partners, employees, agents, associates
and advisers (each such person, a PEL Person) do not make or provide
any representation, warranty or assurance, express or implied, of any
nature in respect of the Information (including, without limitation, as to
the accuracy, reliability or completeness of any of the Information or as
to whether any forward-looking statement will be realized or achieved or
the likelihood of this occurring).
No PEL Person is required or under any obligation to update this
presentation and, except where required by law or applicable Listing
Rules, no PEL Person is required or under any obligation to update the
Information.
To the maximum extent permitted by law, each PEL Person disclaims,
and no PEL Person shall have any, liability of any nature (including,
without limitation, arising from any fault or negligence) arising from or
in connection with (1) any person’s reliance on or use of the Information;
(2) any errors in or omissions from the Information; or (3) any failure to
update or correct the Information.
IMPORTANT NOTICE AND DISCLAIMER
3

DIRECTORS
4
SARAH PARK
ANNA STOVETONY BARCLAY
BRYAN WILLIAMS
ANATOLE MASFEN

1.CHAIRMAN’S ADDRESS
2.CHIEF EXECUTIVE’S ADDRESS
3.QUESTIONS
4.RESOLUTIONS
5.VOTING AND GENERAL BUSINESS
6.MEETING CLOSE
AGENDA
5

PACIFIC EDGE - THE FIRST MOVER IN BLADDER CANCER DIAGNOSTICS
MAJOR GROWTH CATALYST: DRAFT MEDICARE COVERAGE PROPOSED IN MAY 2026
SCIENCE, TECH AND IPCLINICAL EVIDENCE
SUBSTANTIAL MARKET
OPPORTUNITY
GROWTH CATALYST WITH
MEDICARE COVERAGE
Cxbladder tests are patented
non-invasive urine tests that
deliver proven clinical,
economic and patient value
Cxbladder tests are supported by a
robust portfolio of clinical evidence,
and the AUA
1
has recognized Cxbladder
Triage with a ‘Grade A’ evidence rating
– the only urine biomarker to achieve
that rating
The primary symptom of bladder
cancer is hematuria with ~7m
diagnoses each year in the US driving
a global market opportunity of
US$10.2 billion
Draft LCD
2
for Triage & Triage
Plus released in May 2026. Final
LCD expected by Jan 2027
3
.
Novitas confirms claim-by-claim
reimbursement for both tests
6
1.AUA = American Urological Association,
2.LCD = Local Coverage Determination.
3.Novitas must publish the final LCD or retire the draft LCD within 365 days after publishing a draft LCD
4.See slides 44-46 for assumptions
US$10.2b
4
Global Market Opportunity

Jan 2026
Kaiser RWE published
supporting Triage.
Largest ever UBB
1

hematuria study
Feb 2026
CAC Panel expresses
clear support for
UBBs in hematuria
evaluation
May 2026
Novitas publishes
DL40378 with
coverage for Triage
Plus and Triage
Dec 2014
Launch of
Cxbladder
Triage
Nov 2023
Kaiser EMR
integration
goes live
Dec 2022
Lotan et al:
Enhanced
Cxbladder
Tests Deliver
Improved
Performance.
Journal of
Urology
Feb 2018
Cxb Triage
adopted into
Canterbury
Community Health
Pathways with
primary care
referral
2011
2011
Pacific Edge
Diagnostics
New Zealand
(PEDNZ)
established
2012
Dec 2012
Launch of Pacific Edge
Diagnostics USAand
Cxb Detect
2013
Mar 2013
First commercial
sale (Cxb Detect)
for PEDUSA
May 2013
First commercial
sale (Cxb Detect)
for PEDNZ
2014
2015
Dec 2015
Launch of
Cxbladder
Monitor
2016
2018
2019
2020
Jun 2020
Kaiser Permanente,
approves commercial
use of Cxbladder
Jul 2020
Medicare
reimbursement of
Cxbladderat
US$760/test
2021
Aug 2021
Cxbladder reaches
70% public
healthcare
coverage in NZ
2022
2023
2024
May 2024
STRATA podium
presentation at
AUA 2024.
Study published
in Journal of
Urology
Timeline: Company Milestones
2025
Feb 2025
Triage included in AUA
Microhematuria
Guideline
Apr 2025
Medicare non-
coverage
effective
Nov 2025
Triage Plus gets CMS
draft price of
US$1,328
2026
1.UBBs are urine-based biomarkers – a term adopted by AUA in their guidelines

FY26: A YEAR OF STRATEGIC DELIVERY
ADVANCING MEDICARE COVERAGE GOALS; COSTS CONTAINED
8
$2.4M
2H 26CASH
BURN/MONTH
DOWN 27.7% ON
1H 26
-$35.8M
NET LOSSAFTER
TAX UP 19.5%
on FY25
$2.4M
2H 26CASH
BURN/MONTH
DOWN 27.7% ON
1H 26
STRATEGIC HIGHLIGHTS
•February 2026, CAC Panel expresses clear support for UBBs in hematuria evaluation
•May 2026, Novitas publishes draft LCD ‘Urine-based Biomarkers in Patients with
Microhematuria’ (DL40378) supporting coverage of Cxbladder Triage and Triage Plus
•Expect final effective Medicare coverage by the end of 2026.
•Building US commercial payer momentum, with medical policy for hematuria
evaluation tests from insurers covering 10.5 million lives.
•Asia Pacific operations advance towards profitability on a direct cost basis
FINANCIAL HIGHLIGHTS
•FY26 operating revenue fell due to Medicare non-coverage determination; APAC
shows steady growth on smaller volumes
•2H 26 cash burn reduced through careful expense management; targeting a monthly
average cash burn for FY27 of NZ$2.5m vs NZ$2.85m for FY26.
•A post balance date $36.1 million capital raising to strengthen our balance sheet and
drive revenue growth
18,783
COMMERCIAL
TESTS -23.8%
on FY25
$11.5M
OPERATING
REVENUE
-47.4% on
FY25

9
DR PETER MEINTJES
Chief Executive Officer
CHIEF EXECUTIVE’S ADDRESS

VALUE CREATION THROUGH THREE PILLARS
OUR PEOPLE
OUR PROCESSES
OUR IP, KNOWLEDGE
AND EXPERIENCE
OUR CLINICAL STUDIES
PARTNER SITES
OUR INVESTORS
EARLY DETECTION AND
CLINICALLY ACTIONABLE CARE
INNOVATION PIPELINE FOR
CLINICAL APPLICATIONS
INCLUSIVE WORKPLACE
DRIVEN BY OUTCOMES
INCREASED LONG-TERM
SHAREHOLDER VALUE
EXCELLENT PATIENT EXPERIENCE
AND ACCURATE RESULTS
INPUTSOUTPUTS
A VALUES DRIVEN, DIVERSE, RESULTS-FOCUSED CULTURE
SCALABLE PROCESSES, TRAINING & QUALITY SYSTEMS,CONTINUOUS IMPROVEMENT
DIGITALIZED ARCHITECTURE, AUTOMATED OPERATIONS, REAL-TIME ANALYSIS
10

PACIFIC EDGE: LEADER IN URINE-BASED BIOMARKER TESTING
STRONG EXECUTION ON EVIDENCE-PILLAR UNDERPINS FUTURE COMMERCIAL SUCCESS
11
•Draft LCD supporting Medicare coverage of Cxbladder Triage & Triage Plus; Final and
effective LCD expected by end of 2026
•Rigorous clinical evidence program to extend risk thresholds in guidelines/medical
policy to deliver a larger serviceable market
•US Commercial testing stabilizes; set to rise with final coverage
•Medical policy wins with US commercial payers increasing; over 10.5 million lives
now covered with commercial policy for Cxbladder Triage
•Advancing APAC towards profitable operations on a direct cost basis
•Driving long-term enterprise value with product improvements and new products
•Triage Plus at $1,328 and Surveillance Plus at $1,800
1
create higher margin
opportunity and improved unit economics
1.Management estimate of US$1,800 for NMIBC surveillance is based on proposed crosswalk and is not yet priced by Medicare

NOVITAS PROPOSED DRAFT COVERAGE FOR TRIAGE AND TRIAGE PLUS
12
“Use of validated multi-analyte UBBs may be
reasonable and necessary to support risk-
stratification in appropriately counseled,
intermediate-risk patients with MH who are
considering deferral of cystoscopy.”
- DRAFT LCD: ‘Urine-based Biomarkers in Patients
with Microhematuria’ (DL40378)
FINALIZED LCD EXPECTED TO ACCLERATE PACIFIC EDGE’S PATH TO PROFITABILITY
•Triage and Triage Plus proposed for Medicare coverage
•No other biomarkers proposed for Medicare coverage
•Final effective coverage expected before the end of the year
•Final LCD expected to catalyze reimbursement and testing volume
•Our immediate commercial focus is to:
•Improve the unit economics of operating front line sales team
•Shift our customer base to order Triage Plus ($1,328) on every eligible
patient
•Ensuring payment success of >80% on commercial tests by operating
where we have reliable history of commercial success or existing medical
policy and contracting

US$10.2b
Global TAM
1
CXBLADDER MARKET OPPORTUNITY
CXBLADDER OFFERS A SIGNIFICANT ADDRESSABLE GLOBAL MARKET ANNUALLY
~17m0.47m | 2.71m | 3.46m1.7m ~58k ~300k US$1.9b830m
~12m0.34m | 1.96m | 2.5m1.7m ~180k ~1mUS$1.9b600m
APAC
Primary growth
focus due to higher
CMS pricing
NZ market mature.
Australia and SEA in
business development
New market accessed
via IVD / kitted tests
1.Pacific Edge estimate using US$1,328 price for hematuria testing (priced by Medicare) in the US and US$1,800 for NMIBC surveillance (seeking crosswalk price – not yet priced by
Medicare) with next generation products Triage Plus and Surveillance Plus. Other market assumptions for APAC and Europe. See slide 44-46 for details.
2.RDM: Residual Disease Monitoring
3.TRM: Therapeutic Response Monitoring
4.Management estimates derived from referred hematuria data in Woldu et al (2021). MH estimated at 80% and GH at 20%. MH Risk categories: Low 7%, Intermediate 41%, High 52%. See
Slide 44-46 for details.
All
hematuria
Microhematuria
4
Low | Intermediate | High
Gross
4

Hematuria
Annual cases of
bladder cancer
Living with bladder cancerTAMPopulation
SURVEILLANCE
(RDM
2
, TRM
3
, RECURRENCE)
PATIENT/DISEASE MANAGEMENT
(CLINICAL DECISION MAKING)
13
~7m0.20m | 1.14m | 1.46m0.7m ~90k ~750k US$6.4b340m

14
AUA 2027 HEMATURIA GUIDELINE REVIEW IN FOCUS
•STRATA second publication
•Simplify Triage utility messaging; will include the
clinical outcomes of imaging
•AUSSIE and microDRIVE
•Clinical validation of Triage Plus
•MH & GH Pooled Analyses
•Demonstrate concordance between Triage and Triage
Plus
•Demonstrate equivalent performance in all MH risk
categories and GH
•Analyze across age, gender and ethnicity
Collectively, these studies are expected to re-define
the AUA risk stratification thresholds for greater
serviceable market
DRIVING CLINICAL VALUE FOR PHYSICIANS, HOSPITALS AND PAYERS
COMPELLING CLINICAL EVIDENCE CHANGES CLINICAL PRACTICE, MEDICAL POLICY AND GUIDELINES
1.Clinical Utility (CU) - Evidence a test that can usefully change patient management within the context of care for the defined population and indication Clinical Validity (CV) - Evidence a test
works in the same way on an independent eligible population for a given indication. Analytical validity (AV) - Evidence a test is repeatable in the lab for a given indication and population
STUDY
TEST AND EVIDENCE
PUBLICATION DATE
(1)
1. STRATA Clinical Utility
- CU of Triage
Published May 2024
2. Automated RNA & DNA extraction
- AV of Triage, Detect and Monitor
Published September 2024
3. Triage Plus Analytical Validation
- AV of Triage Plus
Published July 2025
4. DRIVE Clinical Validation
- CV of Triage Plus
Published October 2025
5. STRATA second publication
- CU of Triage
Q3 2027
6. AUSSIE Clinical Validation
- CVof Triage Plus
Q3 2026 (+1Q)
7. microDRIVE Clinical Validation
- CV of Triage Plus
Q1 2027 (+1Q)
8. Surveillance Plus Analytical Validation
- AV of Surveillance Plus
Q2 2027 (+3Q)
9. Pooled Analysis MH Clinical Validation
2
- CV of Triage Plus
Q2 2027 (+1Q)
10. Pooled Analysis GH Clinical Validation
2
- CV of Triage Plus
Q2 2027 (+1Q)
11. LOBSTER Clinical Validation
- CV of Monitor/Surveillance Plus
Q3 2027 (+3Q)
12. CREDIBLE Clinical Utility
- CU of Triage Plus
Q1 2028 (at risk)
13. OCTOPUS Clinical Utility
- CU Surveillance Plus
No timeline at this point
1
All dates are calendar year and our best current estimates
2
The MH and GH pooled analysis brings together data from DRIVE, AUSSIE and microDRIVE
Already published evidence
Expected to be published before AUA microhematuria guideline committee initiates next literature review in Q3 2027

INDEPENDENT STUDIES SUPPLEMENT OUR EVIDENCE PORTFOLIO
HIGH IMPACT RESEARCH AT LOW COST
1.All dates are calendar year and our best current estimates
2.Filson et al (2026); Real-World Utility of Cxbladder Triage for Patients with Microhematuria: A Matched Cohort Study, Urology Practice® (2026), doi:
10.1097/UPJ.0000000000000972.
3.BCG: Bacillus Calmette–Guérin is a bacterium instilled into the bladder that triggers an immune response that targets and destroys cancer cells.
4.MIBC: Muscle Invasive Bladder Cancer
INDEPENDENT STUDY FOCUSINSTITUTIONTEST AND EVIDENCE TYPE
PUBLICATION
DATE
1
Real World Utility of Triage in MH: A Matched
Cohort Study
Kaiser Permanente, USCU Triage (RWE)Q1 2026
2
Patient preference and satisfaction of
“biomarkers vs cystoscopy”
Mayo Clinic, USCU MonitorQ3 2026
NZ Hematuria Pathway comparing T/D with
Triage Plus on AUSSIE samples
Canterbury DHBCU of Triage PlusQ3 2026
Retrospective concordance of Triage and Triage
Plus in the Kaiser System
Kaiser Permanente, USCU Triage Plus2027
Test utility in screening patients at risk for
bladder cancer
UT Southwestern, USCU Triage Plus 2027
Test utility in assessing therapy success in a
reduced chemotherapy protocol for upper tract
tumors
Israel Institute of
Technology, Israel
CU Monitor
CU Surveillance Plus
2027
Test utility in assessing response to BCG
3
in high-
grade bladder cancer patients
University of Miami, US
CU Monitor
CU Surveillance Plus
2027
Test utility for the surveillance of MIBC
4
treated
with bladder sparing methods (PRESERVE Trial)
Cleveland Clinic, US
CU Monitor
CU Surveillance Plus
2028
A Randomized Trial of Apalutamide in Non-
Muscle Invasive Bladder Cancer
National Institutes of
Health, US
CU Monitor
CU Surveillance Plus
2029
Already published evidence
15
•Investigator initiated trials (IITs) are
independent studies in which Pacific Edge
typically provides free testing, so provide
significant value at low cost
•IITs extend the evidence portfolio for new
indications of existing tests and may inform
new ‘core’ clinical trials
•IITs are an important part of Key Opinion
Leader (KOL) engagement and generate
publications or podium presentations that
give profile to Cxbladder and Pacific Edge

COMMERCIAL TESTS STABILIZED; SET TO RISE WITH FINAL COVERAGE
16
COMMERCIAL AND TOTAL THROUGHPUT STABILIZED
•Commercial and total throughput stable over
last three quarters
•Sales efficiency improved as sales FTE lowered
to address cash burn
•Seeking to shift commercial product mix to
Triage Plus for higher margins
US TOTAL TEST VOLUME
1
AND COMMERCIAL PRODUCT MIX
1.Total Laboratory Throughput including commercial, pre-commercial and clinical studies testing
2.Pacific Edge has previously used Total Lab Throughput, but has changed its reporting to focus on Commercial throughput, which accounts for the differences in reported figures compared to previous quarterly and half yearly reporting
23%
62%
85%
85%
87%
86%
58%
23%
1%
1%
2%
1%
1%
18%
14%
14%
13%
13%
13%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Q4 25Q1 26Q2 26Q3 26Q4 26Q1 27
PRODUCT MIX (%)
TriageDetectTriage PlusMonitor
5,295
4,600
3,786
3,010
3,375
3,295
1,195
1,122
1,187
1,015
689
540
6,490
5,722
4,973
4,025
4,064
3,835
-
1,000
2,000
3,000
4,000
5,000
6,000
7,000
8,000
Q4 25Q1 26Q2 26Q3 26Q4 26Q1 27
TEST VOLUME
Clinical and non-commercial tests Commercial Volume

COMMERCIAL STRATEGY WITH DRAFT MEDICARE COVERAGE
CONFIGURING OUR SALES TEAM AROUND INTERMEDIATE RISK PATIENTS
•Pacific Edge’s near-term success relies on reducing our cash burn:
•Identify call points with high numbers of intermediate risk microhematuria (IRMH)
patients
•Migrate customers to Triage Plus
•Targeting intermediate risk microhematuria (IRMH) patients
•Women’s health providers are a major opportunity, because IRMH patients are
predominantly female
•IRMH patients are commonly seen by URPS, urogyns, OBGYN and FPMRS
1
•Systems integrated between primary care and secondary care are another major
opportunity
•Urologists frequently triage IRMH patients with APPs, NPs and PAs
2

•Commercial sales teams focused concentrations of demand:
•Integrated Delivery Networks
•Hospital Systems, Academic Institutions, Veterans Association
•Pacific Edge is making selective investments aimed at growing Triage Plus
volume ordered on IRMH patients that have the highest chance of
reimbursement success and delivering consistent revenue
17
1.URPS is Urogynaecology and Reconstructive Pelvic Surgery, urogyn is urogynaecologist, OBGYN is Obstetrician-Gynaecologist and FPMRS is Female Pelvic Medicine and Reconstructive Surgery
2.Advanced Practice Providers (APPs), Nurse Practitioners (NPs) and Physicians Assistants (PAs)
3.Management estimates derived from referred hematuria data in Woldu et al (2021)

PATIENT FEMALE MALE
Low risk 80%20%
Intermediate risk 75%25%
High risk 34%66%
SEX ASSIGNED AT BIRTH FOR HEMATURIA PATIENTS
3

HEALTHCARE PROVIDER TYPE
(SHARE OF PATIENT VOLUME)
3
INTEGRATED DELIVERY NETWORKS
(SHARE OF PATIENT VOLUME)
3
PRIVATE PRACTICE
(SHARE OF PATIENT VOLUME)
3
1.14m
US annual population of
‘intermediate risk’
hematuria evaluation
patients
60%
40%
IDNsPrivate Practice
80%
20%
Large Urology Group
Practices
Community Urology
51%
30%
8%
7%
4%
Hospital Networks
Academic Centers
Veterans Administration
Kaiser Permanente
Other
INTERMEDIATE RISK MICROHEMATURIA SALES APPROACH
INTEGRATED DELIVERY NETWORKS (IDNs) ARE THE TOP TARGET FOR INTERMEDIATE RISK MICROHEMATURIA
18
1.Management estimates derived from referred hematuria data in Woldu et al (2021). MH estimated at 80% and GH at 20%.
MH Risk categories: Low 7%, Intermediate 41%, High 52%. See slides 44-46 for details.
1
684k
456k

US COMMERCIAL PAYERS: MEDICARE POLICY EXPECTED TO UNLOCK VOLUMES
THE US PRIVATE HEALTH INSURANCE MARKET IS A LARGE OPPORTUNITY
•Commercial payers cover almost four times more lives than Medicare
•IRMH patients skew younger, female and commercially insured
•Final coverage policy from Medicare is expected to unlock revenue from
Commercial Payers by:
•Removing a key reason to deny reimbursement
•Providing additional evidence to overturn denials on appeal
•Providing language that commercial payers can adopt in their own
policies
•Leveraging State Biomarker Laws to mandate payment from
commercial payers
•We focus on establishing medical policy directly with payers or through
third parties like Avalon, EviCore, Carelon, Concert Genetics and ECRI
4
1.https://www.census.gov/library/publications/2025/demo/p60-288.html
2.https://www.medicare.gov/about-us
3.https://content.naic.org/sites/default/files/2024-annual-health-industry-commentary.pdf
4.ECRI is the Emergency Care Research Institute
~1,200
US private health
insurance payers
3
66m
Medicare
insured lives
2

223m
US private
insured lives
1

19
PACIFIC EDGE PAYER MIX (2H 26)
60%
20%
16%
2%
2%
COMMERCIAL
MEDICARE
MEDICARE
ADVANTAGE
VETERANS AFFAIRS
MEDICAID AND
MANAGED MEDICAID

APAC CHARTING A PATH TO PROFITABILITY
APAC – SMALL BUT SIGNFICANT
•APAC contributed 19% of operating revenue in
2H 26 with $2.0m in FY26
•APAC cash burn rate
2
of $0.17m in Q1 FY27,
•Repricing in 2025 created on average 25%
more revenue per test
•Triage Plus increased to 8% of product mix in
Q1 27
•Triage Plus has the potential for ~20%
more revenue per test
•APAC proves the ROW concept that can be
replicated in the Middle East, UK and Europe
pending IVD development
20
1.Total Laboratory Throughput in Asia and Pacific including commercial, pre-commercial and clinical studies testing
2.APAC Commercial and Clinical Operations cash burn figure is calculated on a director cost basis and excludes R&D costs
APAC TOTAL TEST VOLUME
1
AND COMMERCIAL PRODUCT MIX
75%
53%
45%
44%
41%
37.8%
15%
34%
43%
43%
46%
41.8%
0%
0%
0%
2%
1%
7.6%
10%
13%
12%
11%
12%
12.8%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Q4 25Q1 26Q2 26Q3 26Q4 26Q1 27
PRODUCT MIX (%)
TriageDetectTriage PlusMonitor
967
1,014
971
1,001
1,026
1,158
120
154
339
409
492
123
1,087
1,168
1,310
1,410
1,518
1,281
-
200
400
600
800
1,000
1,200
1,400
1,600
Q4 25Q1 26Q2 26Q3 26Q4 26Q1 27
TEST VOLUME
Clinical and non-commercial tests Commercial Volume

21
NEXT GENERATION PRODUCTS ALREADY DELIVERING STRATEGIC VALUE
TRIAGE PLUS AND SURVEILLANCE PLUS OFFER SUPERIOR PERFORMANCE, PRICING AND MARGIN
ADVANCING IVD DEVELOPMENT FOR INTERNATIONAL MARKETS
•Triage Plus and Surveillance Plus will be offered as CAP/CLIA-
approved LDTs
1
providing service to the entire USA
•International markets require a different approach in which Pacific
Edge seeks to create a ‘kitted’ IVD medical device
•Pacific Edge is simplifying its tests to create Triage Plus IVD for
decentralized lab deployment and international market expansion.
•Key objectives:
•Establishing IVD regulatory framework for our next
generation tests that includes IVD-R (Europe), FDA (USA) and
ISO-13485
2
(International)
•Prototype development plan is in place and ready to be
implemented subject to budget approval
1.CAP is the College of American Pathologists, CLIA is the Clinical Laboratory Improvement Amendments and LDT is a laboratory developed test
2.IVD-R European In Vitro Diagnostic Regulation; FDA, US Food and Drug Administration; ISO International Organization for Standardization

OUTLOOK
22

OUTLOOK
POSITIONED TO UNLOCK VALUE THROUGH UPCOMING COMMERCIAL, CLINICAL AND INNOVATION MILESTONES
LONG-TERM VALUE CREATION
RESEARCH INNOVATION
MEDIUM-TERM VALUE CREATION
CLINICAL EVIDENCE GENERATION
NEAR-TERM VALUE CREATION
COMMERCIAL CATALYSTS
•Case-by-case reimbursement for Triage
and Triage Plus under draft LCD
•Final LCD published by end of 2026
•US customers adopt Triage Plus at
US$1,328/test
•Building US Commercial payer medical
policy momentum
•Health New Zealand National Pathway
for Cxbladder
•Evidence generation program delivers
sustained strategic value
•US commercial payer policy for Triage
and Triage Plus drives test adoption
•AUA guideline review (2027/28)
expected to expand serviceable market
•Investigator initiated trials (IITs) generate
novel evidence for new indications
•Triage Plus and Surveillance Plus deliver
better patient outcomes at higher
margin pricing for improved unit
economics
•Targeting SurveillancePlus CPT-PLA
coding submission in June 2027 and
claim-by-claim revenue after 1 Jan 2028
•Seeking US$1,800 CMS pricing for
Surveillance Plus in FY28
•Product simplification and kitted IVD
products enable de-centralized
deployment in international markets
23

24
SIMON FLOOD
Chairman

QUESTIONS
25

RESOLUTIONS
26

VOTING
27

RESOLUTION 1: AUDITORS’ REMUNERATION
28
“To authorise the Directors to fix the auditors’ remuneration for the ensuing year.”

RESOLUTION 2: BRYAN WILLIAMS RE-ELECTION
29
“That Bryan Williams, who retires in accordance with NZX Listing Rule 2.7.1 and is
eligible for re-election, be re-elected as a Director of the Company.”

RESOLUTION 3: SIMON FLOOD ELECTION
30
“That Simon Flood, who retires in accordance with NZX Listing Rule 2.7.1 and is
eligible for election, be elected as a Director of the Company.”

RESOLUTION 4: PAYMENT TO SIMON FLOOD
31
“That the payment in cash of $12,699 to Simon Flood, being unpaid Director
remuneration that has accrued to him in respect of the period from 19 December
2025 to 31 March 2026, as described in the Explanatory Notes, be approved for all
purposes, including NZX Listing Rule 2.11.1.”

RESOLUTION 5: APPROVAL OF SHARE ISSUE
32
“That the issue of 152,561,001 Shares under NZX Listing Rule 4.5.1, being Shares
issued under the Placement, Shares issued to certain participants in the Retail Offer,
and Shares issued in consideration for professional services provided in connection
with the Placement and Retail Offer, be approved and ratified for all purposes,
including NZX Listing Rule 4.5.1(c)

RESOLUTION 6: ISSUE OF SHARES TO CERTAIN PARTICIPANTS
33
“That the issue of 59,998,716 Shares under NZX Listing Rule 4.3.1(c), being Shares
issued to certain participants in the Retail Offer, be approved and ratified for all
purposes, including paragraph (a) of the definition of “share purchase plan” in the NZX
Listing Rules.”

PROXY VOTING DIRECTIONS
34
RESOLUTION FOR
*
OPEN
*
AGAINST
*
TOTAL
**
1. Auditors’ remuneration 571,843,459 (97.4%)14,836,084 (2.5%)406,612 (0.7%)587,086,155 (47.3%)
2. Re-election of Bryan Williams 570,426,875 (97.1%)14,839,284 (2.5%)2,067,893 (0.4%)587,334,052 (47.3%)
3. Election of Simon Flood571,784,791 (97.4%)14,839,284 (2.5%)657,390 (0.1%)587,281,465 (47.3%)
4. Payment to Simon Flood571,026,067 (98.1%)10,250,528 (1.8%)1,072,708 (0.2%)582,349,303 (46.9%)
5. Approval of share issue 383,502,592 (97.3%)10,250,528 (2.6%)448,731 (0.1%)394,201,851 (31.7%)
6. Issue of shares to certain
participants
521,723,100 (97.1%)14,835,739 (2.8%)945,324 (0.2%)537,504,163 (43.3%)
*Percentage figures in the ‘For’, ‘Open’ and ‘Against’ columns indicate proportion of total votes notified (excludes abstentions)
** Percentage figures in the ‘Total’ column indicate total votes notified (excludes abstentions) against issued capital.

GENERAL BUSINESS
35

MEETING CLOSE
36

APPENDIX
37

BLADDER CANCER – A SIGNIFICANT GLOBAL HEALTHCARE CHALLENGE
AN INVASIVE STATUS QUO – A NON-INVASIVE OPPORTUNITY
38
1.Sievert et al (2009) Economic aspects of bladder cancer: what are the benefits and costs? World J Urol. 2009 Mar 7;27(3):295–300. doi: 10.1007/s00345-009-0395-z
2.World Cancer Research Fund. Statistics are from 2022.
3.Average recurrence for low grade non-muscle invasive bladder cancer as published in Palou J et al (2012): Eur Urol 2012; 62: 118.
4.The Survey was conducted by the Bladder Cancer Advocacy Network (BCAN)
5.Company estimate
1
st

Costliest cancer to
treat on a per-
patient basis
1
6
th
Most common
cancer in men
2
9
th
Most common
cancer world-wide
2
~614K
Annual cases
and growing
2
>220K
Annual
Deaths
2
>50%
Recurrence
3
4.9m
5
Annual cystoscopies avoided globally if Cxbladder tests were used to
evaluate intermediate risk patients presenting with hematuria
5

CYSTOSCOPY CXBLADDER TEST
•Cystoscopy – an invasive, uncomfortable and costly procedure to visually
inspect the bladder by inserting a camera into the urethra
•The standard hematuria workup, where the majority of patients are
found to have no cancer
•In a survey
4
of US NMIBC patients under surveillance, 78% said they
experienced some pain, with 25% saying it was moderate to “worst
imaginable”
•The result is systemic over-proceduralization: millions of avoidable
cystoscopies every year, adding cost, patient discomfort, infection risk and
urology backlog
•Non-invasive genomic urine testing like Cxbladder can rule out cancer and
prioritize patients who truly need cystoscopy – a large unmet clinical need
•Women are an under-served market, with hematuria frequently
dismissed as urinary tract infections (UTI)
Source: Nursing Skills

CXBLADDER: TESTS TO RULE OUT CANCER OR PRIORITIZE PATIENTS
THE PATIENT CARE PATHWAY
1.RDM: Residual Disease Monitoring
2.TRM: Therapeutic Response Monitoring
3.NMIBC: non-muscle invasive bladder cancer
4.AUA: American Urological Association
5.AV, CV, CU are Analytical Validity, Clinical Validity, and Clinical Utility which are required for medical policy and guidelines
>130,000
Patients that have used
Cxbladder
>5,000
Urologists that have ordered
Cxbladder
>30
Publications demonstrating AV,
CV or CU evidence
5

Grade A
Evidence rating by the AUA
4
in its
2025 Microhematuria Guideline

•Cxbladder avoids invasive, unnecessary procedures saving >US$500/patient driving down costs for health systems and payers
2
•Only 63% of counties in the US have a registered urologist
3
and only 13% of high-risk microhematuria patients receiving a cystoscopy
4

•The US population is ageing and the urologists per person over 65 is falling (from 23.8/100k to 15.8/100k in 2035
5
) potentially delaying diagnosis
•Medicare reimbursement for cystoscopy has declined from US$204.80 in 2023 to US$172.80 in 2026
6
1.AUA Guidelines cite incidence of bladder cancer in microhematuria risk categories from 0.4-6%. 5% is an example
2.Tyson et al (2024) Budgetary Impact of Including the Urinary Genomic Marker Cxbladder Detect in the Evaluation of Microhematuria Patients - PubMed (PMID: 37914255)
3.https://www.auanet.org/research-and-data/aua-census/census-results
4.https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.25048
5.Nam et al. (2021) Projected US Urology Workforce per Capita, 2020-2060 JAMA Network Open Published Online:November16,2021
6.https://www.cms.gov/medicare/physician-fee-schedule/search
DRIVING ECONOMIC VALUE FOR PATIENTS, HOSPITALS AND PAYERS
CXBLADDER DELIVERS CLINICAL UTILITY, PATIENT SATISFACTION AND ECONOMIC VALUE
Illustration shows incidence of bladder cancer in microhematuria
populations at 5%
1
With Triage Plus, 85% of patients can avoid cystoscopy, 15% receive
cystoscopy to find the same 5 cancer patients
40
CANCER INCIDENCE IN MICROHEMATURIA PATIENTSCYSTOSCOPIES SAFELY AVOIDED USING CXBLADDER
Cystoscopy
No cancer
Cystoscopy
Cancer
No cystoscopy
No cancer
Cystoscopy
Cancer
Cystoscopy
No cancer

Calendar year
Pre
2023
202320242025202620272028
Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2
STRATA
DRIVE
AUSSIE
microDRIVE
Pooled CV
CREDIBLE
HEMATURIA EVALUATION FIVE YEAR CLINICAL STUDIES ROADMAP
*
*
*
*
*
Publication Submitted
Records review / follow-up
Database lock
Legend:
Pre-activation (docs, CTA etc)
SIV
Enrollment
Data Cleaning
*
DBL
DBL
DBL
41

Calendar year
Pre
2023
202320242025202620272028
Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2
“The 1800”
1
LOBSTER
OCTOPUS
*
SURVEILLANCE FIVE YEAR CLINICAL STUDIES ROADMAP
42
Publication Submitted
Records review / follow-up
Database lock
Legend:
Business case approved
SIV
Enrollment
Data Cleaning
*
DBL
Scheduled surveillance visits
CAB
2
1.“The 1800” is the Surveillance Plus development dataset
2.CAB is the Pacific Edge Clinical Advisory Board. It was convened at SUO in Arizona to review and confirm the clinical study trial design for OCTOPUS

THE CXBLADDER SUITE
Hematuria EvaluationNMIBC
1
Surveillance
Cxbladder Product
TriageDetectTriage PlusMonitorSurveillance Plus
Product Summary
Risk stratification of
microhematuria patients to
rule out the majority of those
patients from further workup
for bladder cancer
Adjunctive use with
cystoscopy on hematuria
patients to resolve diagnostic
dilemmas (e.g. equivocal
cystoscopy and atypical
cytology)
Risk stratification and
adjunctive use on any
hematuria patient with
improved performance over
Triage and Detect
Alternative to cystoscopy
for NMIBC patients
undergoing surveillance
for recurrence
Alternative to cystoscopy for
NMIBC patients undergoing
surveillance for recurrence.
Currently in development,
showing improved
performance
Analytical composition
5 RNA biomarkers + patient clinical
factors
5 RNA biomarkers
5 RNA biomarkers + 6 DNA
SNVs from 2 genes (FGFR3/
TERT)
5 RNA biomarkers + patient
tumor history
13 SNVs across 5 genes
2 fusions associated with 1 gene
1 methylation marker
2 control markers
Test Performance
Hematuria
2
Sn: 95%
Sp: 45%
NPV: 99%
PPV: N/A
Hematuria
3
Sn: 82%**
Sp: 94%*
NPV: 97%**
PPV: 68%*
Hematuria
4
Sn: 93.6%****
Sp: 98.2%***
NPV: 99.4%****
PPV: 74.6%***
All risk groups
5,6
Sn: 93%
Sp: N/A
NPV: 97%
PPV: N/A
All Risk Groups
Sn: Not yet published
Sp: Not yet published
NPV: Not yet published
PPV: Not yet published
When is it used?
Prior to cystoscopyPrior to cystoscopy / as an adjunct / 3 weeks post cystoscopyAs a non-invasive surveillance alternative
Commercially
available?

Commercially available in APAC
and under “early access” in US,
pending coverage

CPT-PLA code targeted for Dec 2026
Reimbursed on A58917 in Jul 2027
Medicare Pricing (USD)
$760$760
$1,328$760$1,800 (seeking by crosswalk)
1.NMIBC: non-muscle invasive bladder cancer
2.Kavalieris et al. (2015) A segregation index combining phenotypic (clinical characteristics) and genotypic (gene expression) biomarkers from a urine sample to triage out patients presenting with hematuria who have a low
probability of urothelial carcinoma. BMC Urol 2015;15:23.
3.O’Sullivan et al. (2012) A multigene urine test for the detection and stratification of bladder cancer in patients presenting with hematuria. J Urol 2012; 188:741–7.
4.Harvey et al. (2025) Analytical Validation of the Cxbladder® Triage Plus Assay for Risk Stratification of Hematuria Patients for Urothelial Carcinoma. Diagnostics. 2025; 15(14):1739. https://doi.org/10.3390/diagnostics15141739
5.Kavalieris et al. (2017) Performance Characteristics of a Multigene Urine Biomarker Test for Monitoring for Recurrent Urothelial Carcinoma in a Multicenter Study. J Urol 2017;197:6,1419-1426.
6.Lotan et al. (2017) Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations. Elsevier; 2017; 1–8.
* When higher 0.23 cut point on test report is used
** When lower 0.12 cut point on test report is used
*** When higher 0.54 cut point on test report is used
**** When lower 0.15 cut point on test report is used
43

SOURCES AND ASSUMPTIONS - TOTAL ADDRESSABLE MARKET (US)
44
REGIONSTATISTICSOURCE
UNITED STATES
Population 341,762,685https://www.census.gov/popclock/
Incidence of hematuria7,000,000
Presentation from Dr Sia Daneshmand (Director of
Urologic Oncology and Clinical Research, USC) July 2019
Referred for clinical workup3,500,000
Presentation from Dr Sia Daneshmand (Director of
Urologic Oncology and Clinical Research, USC) July 2019
Proportion of gross hematuria amongst
those referred for clinical workup700,000Pacific Edge estimate
Proportion of microhematuria amongst
those referred for clinical workup2,800,000Pacific Edge estimate
Proportion of low-risk microhematuria 200,000
Woldu, S, et al. Evaluation of the New American Urological
Association Guidelines Risk Classification for Hematuria;
Pacific Edge estimates to account for AUA 2025
guidelines
Proportion of intermediate-risk
microhematuria 1,140,000
Woldu, S, et al. Evaluation of the New American Urological
Association Guidelines Risk Classification for Hematuria;
Pacific Edge estimates to account for AUA 2025
guidelines
Proportion of high-risk microhematuria 1,460,000
Woldu, S, et al. Evaluation of the New American Urological
Association Guidelines Risk Classification for Hematuria;
Pacific Edge estimates to account for AUA 2025
guidelines
Annual cases of bladder cancer 84,870
National Cancer Institute
Patients living with bladder cancer 744,044
National Cancer Institute
Test opportunities 4,416,066Pacific Edge estimate
Price of Cxbladder (US$)
$1,328 for Cxbladder Triage Plus, $1,800 for Cxbladder
Monitor
TAM (US$billion)$6.4

SOURCES AND ASSUMPTIONS - TOTAL ADDRESSABLE MARKET (EUROPE)
45
REGIONSTATISTICSOURCE
EUROPE (EXCLUDING
RUSSIA)
Population
600,000,000World-population - Europe
World-population - Russia
Incidence of hematuria12,000,000
Science Direct
Referred for clinical workup6,000,000
Presentation from Dr Sia Daneshmand (Director of
Urologic Oncology and Clinical Research, USC) July 2019
Proportion of gross hematuria amongst
those referred for clinical workup1,200,000Pacific Edge estimate
Proportion of microhematuria amongst
those referred for clinical workup4,800,000Pacific Edge estimate
Proportion of low-risk microhematuria 340,000
Woldu, S, et al. Evaluation of the New American Urological
Association Guidelines Risk Classification for Hematuria;
Pacific Edge estimates to account for AUA 2025
guidelines
Proportion of intermediate-risk
microhematuria 1,960,000
Woldu, S, et al. Evaluation of the New American Urological
Association Guidelines Risk Classification for Hematuria;
Pacific Edge estimates to account for AUA 2025
guidelines
Proportion of high-risk microhematuria 2,500,000
Woldu, S, et al. Evaluation of the New American Urological
Association Guidelines Risk Classification for Hematuria;
Pacific Edge estimates to account for AUA 2025
guidelines
Annual cases of bladder cancer 180,000
Uroweb
Patients living with bladder cancer 900,000Pacific Edge estimate - 5 years of annual cases
Test opportunities 7,010,000Pacific Edge estimate
Price of Cxbladder EURO€245Pacific Edge estimate
TAM (US$billion)$1.9

SOURCES AND ASSUMPTIONS - TOTAL ADDRESSABLE MARKET (APAC)
46
REGIONSTATISTICSOURCE
APAC (EXCLUDING INDIA
AND CHINA)
Population
830,000,000
World population - Southeast Asia
Population Pyramid - Japan
Population Pyramid - Hong Kong
Incidence of hematuria16,600,000
Science Direct
Referred for clinical workup
8,300,000
Presentation from Dr Sia Daneshmand (Director of
Urologic Oncology and Clinical Research, USC) July 2019
Proportion of gross hematuria amongst
those referred for clinical workup
1,660,000
Pacific Edge estimate
Proportion of microhematuria amongst
those referred for clinical workup
6,640,000
Pacific Edge estimate
Proportion of low-risk microhematuria
470,000
Woldu, S, et al. Evaluation of the New American Urological
Association Guidelines Risk Classification for Hematuria;
AUA 2025 guidelines
Proportion of intermediate-risk
microhematuria
2,710,000
Woldu, S, et al. Evaluation of the New American Urological
Association Guidelines Risk Classification for Hematuria;
AUA 2025 guidelines
Proportion of high-risk microhematuria
3,460,000
Woldu, S, et al. Evaluation of the New American Urological
Association Guidelines Risk Classification for Hematuria;
AUA 2025 guidelines
Annual cases of bladder cancer
58,000
WHO
Hong Kong
Patients living with bladder cancer 290,000Pacific Edge estimate - 5 years of annual cases
Test opportunities 3,531,000Pacific Edge estimate
Price of Cxbladder (US$)$550Pacific Edge estimate
TAM (US$billion)$1.9

FOR MORE INFORMATION:
Dr. Peter Meintjes
Chief Executive Officer
email: peter.meintjes@pelnz.com
Grant Gibson
Chief Financial Officer
email: grant.gibson@pelnz.com
Pacific Edge
87 St David Street, PO Box 56, Dunedin, New Zealand
P +64 3 577 6733 Within NZ 0800 555 563
email: investors@pacificedge.co.nz
www.pacificedgedx.com
47

---

PACIFIC EDGE 2026 ANNUAL SHAREHOLDERS’ MEETING
CHAIRMAN’S ADDRESS
Welcome everyone to Pacific Edge’s 2026 Annual Shareholders’ Meeting. My name is Simon
Flood, and I’m a Director and Chair of Pacific Edge.
This is my first Annual Shareholders’ Meeting having been appointed to the Board in December
last year and assumed the role of Chair following Chris Gallaher’s retirement.
I am very pleased to welcome shareholders joining us here in Auckland and those participating
online.
I would like to spend a few moments putting Pacific Edge’s current position in context — where
we’ve been, the opportunity we have in front of us, why we’re positive about the future, and to
clearly set out what we believe we need to do to realize the opportunities we see.
When I joined Pacific Edge late last year, I did so because I believed the company had
assembled something rare and tremendously exciting in a sector that I have a strong affinity
with: patented, non-invasive tests with proven clinical utility, a substantial and expanding
evidence base, a recognised patient and healthcare system need, and a meaningful global
opportunity.
I also believed that the Medicare process, while challenging, would ultimately recognize the
value Cxbladder offers.
That conviction has strengthened.
The draft Local Coverage Determination (LCD) published by Medicare Administrative Contractor
Novitas in May proposes Medicare coverage for both Cxbladder Triage and Cxbladder Triage
Plus — our tests for the evaluation of patients presenting with hematuria, blood in urine.
Importantly, those are the only biomarkers proposed to be reimbursable under that policy.
This is a company-defining milestone and a significant validation of our evidence-led strategy
and is major step forward to an opportunity worth — in revenue terms — US$10.2 billion
annually.
Our work is incomplete in this regard, but the draft LCD is a huge step forward and a hard-won
recognition for the years of work put in by our Team lead by Pete Meintjes. The LCD remains
draft, and disciplined execution remains essential as we await confirmation of a final LCD which
we hope to receive before the end of this year. The difference that the draft LCD makes is that
it gives Pacific Edge a clearer reimbursement pathway and a legitimacy that confirms Cxbladder
as the leader in its field, and that’s a great place for us to start rebuilding sales momentum.
Bladder cancer diagnosis often begins with the evaluation of the causes of hematuria and there
are millions of hematuria evaluations each year in the United States.
Cxbladder is designed to help identify hematuria patients at a low risk of cancer. Appropriately
used, it will ensure that patients are able to receive an accurate diagnosis, that was previously
only available if they underwent a cystoscopy, a procedure many have chosen to avoid given its
invasive nature.
The risk stratification of patients by clinicians also ensures that higher-risk patients continue
through the appropriate pathway which has been freed up by the redirection of those low and

2

intermediate risk patients. That delineation of care is valuable for patients, clinicians, and the
healthcare system as a whole.
Pacific Edge is now better positioned to pursue that opportunity than it was twelve months ago.
The draft LCD deepens the commercial and scientific moat around the business. The inclusion
of Triage Plus also opens the potential for improved unit economics.
Growing commercial payer support in the United States from what effectively amounts to a
validation of our products will in turn support growth in other markets such as the Asia Pacific
where we are seeing steady progress.
This next slide puts the current moment in context.
Pacific Edge’s progress has been the result of a long and deliberate journey: building evidence,
establishing diagnostic operations in New Zealand and the United States, launching Cxbladder
products, securing early commercial use, and working over many years to embed our tests into
clinical practice.
For a diagnostics company, adoption is earned through evidence, demonstrated clinical utility,
better patient pathways, and the confidence of clinicians and payers. Pacific Edge has done that
hard work.
The achievements of the last two years have been significant markers on that journey. They
include:
- the groundbreaking STRATA study that established the clinical utility of Cxbladder Triage;
- the inclusion of that test in the American Urological Association Guideline in 2025;
- the resounding support for the test expressed by the expert Contractor Advisory
Committee convened by Novitas in February of this year; and
- now the draft LCD.
Together they have endorsed our strategy of placing thoroughly researched and validated
clinical evidence at the heart of value creation. Those elements also give us a highly credible
pathway to convert market access into growth and, over time, profitability.
As shareholders will be well aware this journey has not been linear. The Medicare non-coverage
period was a serious challenge.
But the long-term direction of travel is clear: the company has continued to build evidence,
protect its intellectual property and develop products with the potential to improve the standard
of care in bladder cancer diagnostics.
That is also the basis for my own conviction.
I am aligned with shareholders not only as Chair, but as someone who has chosen to invest
personally in Pacific Edge. I have done so alongside my fellow directors, management and the
broader team because we believe the opportunity is real, the evidence is increasingly
recognized, and the company now has a pathway to create substantially greater value if it
executes well.
Turning now to FY26.
The financial results reflect the impact of Medicare non-coverage. Commercial test volumes and
operating revenue were down, and the company recorded a large net loss. Those have been
real challenges.

3

Still, as I have highlighted FY26 was a year of strategic delivery. Pacific Edge preserved the core
assets required to scale, managed costs carefully, reduced cash burn in the second half, and
completed a capital raising to support the next phase of the strategy, which is all about delivery
and growth.
Most importantly, FY26 delivered the draft LCD. The company also built commercial payer
momentum in the United States, while Asia Pacific continued to advance through clinical
pathway adoption and commercial progress.
These developments broaden the opportunity beyond Medicare alone.
Triage Plus also improves the outlook. Its higher performance and Medicare price create the
potential to improve revenue per reimbursed test, margins and the company’s path to
profitability. Surveillance Plus remains an important future opportunity, with further clinical
validation and reimbursement steps ahead.
Pacific Edge is in a materially stronger strategic position than it was a year ago.
The message I want to leave shareholders with is this: Pacific Edge has been through a difficult
period, but it has not stood still. It has protected and strengthened the foundations of the
business.
As Chair, I am excited about the future of Pacific Edge.
I am also realistic about the execution required. We will continue to be measured, disciplined
and transparent and I believe the company now can convert its first-mover position, clinical
evidence, and product innovation into meaningful value for patients, healthcare systems, and
shareholders.
On behalf of the Board, I thank our shareholders for your patience and support, the Pacific Edge
team for their commitment, and the clinical community whose engagement has helped to bring
the company to this important point.
I will now hand over to Peter, who will speak in more detail about the company’s operational
progress, commercial priorities, and outlook.
/end